EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSJJAG00000008663
Gene Symbol: F2RL3
3 Cross references
197 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSJJAG00000015494
Gene Symbol: FAU
3 Cross references
206 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSJJAG00000011850
Gene Symbol: FXYD2
3 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSJJAG00000019918
Gene Symbol: FYN
3 Cross references
261 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSJJAG00000015379
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSJJAG00000001613
Gene Symbol: GPR84
2 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSJJAG00000001670
Gene Symbol: HCK
3 Cross references
205 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSJJAG00000021816
Gene Symbol: ITK
3 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSJJAG00000022247
Gene Symbol: JAK1
3 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSJJAG00000012271
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSJJAG00000012029
Gene Symbol: JAK3
3 Cross references
103 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSJJAG00000002257
Gene Symbol: KIT
3 Cross references
265 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).